Bloodwork question about epitalon. Baseline, eight months in, and the numbers moved in a direction I did not expect.
What surprised me is how much of the perceived benefit was routine and attention rather than pharmacology.
I would rather have a narrow conclusion and be right than a broad one and be interesting.
What the peptide class does pharmacologically does not require the subjective effect to be large to be real.
The interesting question is not whether it works but for whom and at what cost.
An inconclusive account is useful if it stops the next person mistaking a story for a controlled comparison.
Test one thing at a time. It feels slower and it is the only way to learn anything.
I would take the narrow conclusion. Broad ones are more interesting and less true.